P. Lyle

发表

A multicenter, randomized, double-blind, placebo-controlled, 8-week trial of the efficacy and tolerability of once-daily losartan 100 mg/hydrochlorothiazide 25 mg and losartan 50 mg/hydrochlorothiazide 12.5 mg in the treatment of moderate-to-severe essential hypertension.

R. Zeldin, A. Gradman, W. Brady, 2002, Clinical therapeutics.

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy.

J. Lunceford, B. Brenner, H. Parving, 2008, Journal of the American Society of Nephrology : JASN.

Effect of ACE insertion/deletion and 12 other polymorphisms on clinical outcomes and response to treatment in the life study

B. Nordestgaard, U. de Faire, Peggy H. Wong, 2010, Pharmacogenetics and genomics.

A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension*

S. Oparil, S. Julius, N. Abate, 2008 .

Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study).

R. Devereux, S. Kjeldsen, M. Olsen, 2007, American Journal of Cardiology.

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study

S. Oparil, P. Okin, R. Devereux, 2008, Hypertension.

Does albuminuria predict cardiovascular outcomes on treatment with losartan versus atenolol in patients with diabetes, hypertension, and left ventricular hypertrophy? The LIFE study.

K. Borch-Johnsen, S. Snapinn, M. Olsen, 2006, Diabetes care.

Hospitalizations for new heart failure among subjects with diabetes mellitus in the RENAAL and LIFE studies.

P. Kowey, B. Brenner, R. Devereux, 2005, The American journal of cardiology.

First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patient with heart failure: A double-blind, randomized, multicenter study

S. Gottlieb, J. Kostis, R. Lang, 1994 .

The effect of losartan compared with atenolol on the incidence of revascularization in patients with hypertension and electrocardiographic left ventricular hypertrophy. The LIFE study

M. Nieminen, R. Devereux, M. Olsen, 2006, Journal of Human Hypertension.

Losartan and the United States costs of end-stage renal disease by baseline albuminuria in patients with type 2 diabetes and nephropathy.

W. Keane, S. Shahinfar, C. Alexander, 2004, Kidney international. Supplement.

Safety and tolerability of lisinopril in older hypertensive patients.

P. Lyle, J. Rush, Janet E. Rush, 1988, The American journal of medicine.

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

M. Nieminen, S. Oparil, U. de Faire, 2009, Journal of hypertension.

First-dose effects of enalapril 2.5 mg and captopril 6.25 mg in patients with heart failure: a double-blind, randomized, multicenter study. The Enalapril-Captopril Investigators.

S. Gottlieb, J. Kostis, R. Lang, 1994, American heart journal.

Pulse Pressure and Effects of Losartan or Atenolol in Patients With Hypertension and Left Ventricular Hypertrophy

M. Nieminen, S. Oparil, U. de Faire, 2005, Hypertension.

A double-blind, randomized study evaluating losartan potassium monotherapy or in combination with hydrochlorothiazide versus placebo in obese patients with hypertension.

S. Oparil, S. Julius, N. Abate, 2008, Current medical research and opinion.

Hypertension and medical informatics.

C. Ferrario, P. Lyle, W. McBride, 2003, Journal of the National Medical Association.

Atenolol as a comparator in outcome trials in hypertension: A correct choice in the past, but not for the future?

R. Devereux, S. Kjeldsen, B. Dahlöf, 2007, Blood pressure.

A multicenter, randomized, double-blind, parallel-group trial of the antihypertensive efficacy and tolerability of a combination of once-daily losartan 100 mg/hydrochlorothiazide 12.5 mg compared with losartan 100-mg monotherapy in the treatment of mild to severe essential hypertension.

Hongyan Zhang, S. Shahinfar, P. Feig, 2006, Clinical therapeutics.

Targeting the renin–angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

M. Nieminen, S. Oparil, U. de Faire, 2005, Expert opinion on emerging drugs.

An analysis of cholesterol control and statin use in the Losartan Intervention for Endpoint Reduction in Hypertension Study.

M. Nieminen, R. Devereux, S. Kjeldsen, 2003, Clinical therapeutics.

The effect of angiotensin receptor blockers for preventing atrial fibrillation

R. Devereux, K. Wachtell, P. Lyle, 2007, Current hypertension reports.

Use of beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers to prevent atrial fibrillation

R. Devereux, K. Wachtell, P. Lyle, 2006, Current cardiology reports.

The left atrium, atrial fibrillation, and the risk of stroke in hypertensive patients with left ventricular hypertrophy

P. Okin, R. Devereux, E. Gerdts, 2008, Therapeutic Advances in Cardiovascular Disease.

The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes.

R. Toto, Z. Zhang, S. Shahinfar, 2008, Kidney international.

Risk scores for predicting outcomes in patients with type 2 diabetes and nephropathy: the RENAAL study.

Zhongxin Zhang, Giuseppe Remuzzi, Janet B McGill, 2006, Clinical journal of the American Society of Nephrology : CJASN.

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

W. Keane, P. Lyle, 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.

Predictors of cardiovascular events in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study

M. Nieminen, S. Oparil, U. de Faire, 2009, Blood pressure.

Losartan: lessons learned from the RENAAL study

B. Brenner, W. Keane, S. Shahinfar, 2006, Expert opinion on pharmacotherapy.

Fixed combination of losartan and hydrochlorothiazide and reduction of risk of stroke

S. Oparil, S. Kjeldsen, J. Kizer, 2007, Vascular health and risk management.

The Effects of Losartan Compared to Atenolol on Stroke in Patients With Isolated Systolic Hypertension and Left Ventricular Hypertrophy. The LIFE Study

M. Nieminen, S. Oparil, R. Devereux, 2005, Journal of clinical hypertension.

Losartan for the treatment of hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study

R. Devereux, P. Lyle, 2004, Expert opinion on pharmacotherapy.

The effect of baseline physical activity on cardiovascular outcomes and new‐onset diabetes in patients treated for hypertension and left ventricular hypertrophy: the LIFE study

S. Julius, J. Kizer, B. Dahlöf, 2007, Journal of internal medicine.

Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study

R. Devereux, S. Kjeldsen, M. Olsen, 2007, Journal of Human Hypertension.

Kidney disease and cardiovascular disease: implications of dyslipidemia.

W. Keane, P. Lyle, 2005, Cardiology clinics.

Treatment of type 2 diabetic patients with kidney disease with AT1-receptor antagonists: lessons from recent trials

B. Brenner, W. Keane, S. Shahinfar, 2002, Clinical and Experimental Nephrology.

Effects of Losartan in Women With Hypertension and Left Ventricular Hypertrophy: Results From the Losartan Intervention For Endpoint Reduction in Hypertension Study

S. Oparil, P. Okin, R. Devereux, 2008, Hypertension.